N4 Pharma (N4P)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.38p
   
  • Change Today:
      0.000p
  • 52 Week High: 3.07
  • 52 Week Low: 0.35
  • Currency: UK Pounds
  • Shares Issued: 832.28m
  • Volume: 0
  • Market Cap: £3.12m

Latest ShareCast News

N4 Pharma reports narrower full-year operating loss

By Josh White

Date: Friday 06 Jun 2025

(Sharecast News) - N4 Pharma reported a reduced operating loss of £1.22m for 2024 on Friday, down from £1.42m the prior year, as the biotech company continued to develop its proprietary Nuvec gene delivery platform.

N4 Pharma files for new UK patent

By Josh White

Date: Wednesday 04 Dec 2024

(Sharecast News) - N4 Pharma, a pharmaceutical company specializing in RNA therapeutics, announced the filing of a new patent with the UK patent office on Wednesday, for its oral anti-inflammatory treatment targeting irritable bowel disease (IBD).

N4 Pharma reports positive progress with SRI collaboration

By Josh White

Date: Tuesday 20 Aug 2024

(Sharecast News) - N4 Pharma, a specialist pharmaceutical company focused on the development of Nuvec, a novel delivery system for cancer treatments, gene therapy, and vaccines, updated the market on its collaboration with SRI International on Tuesday.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

N4 Pharma Market Data

Currency UK Pounds
Share Price 0.38p
Change Today 0.000p
% Change 0.00 %
52 Week High 3.07
52 Week Low 0.35
Volume 0
Shares Issued 832.28m
Market Cap £3.12m

N4 Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
51.85% below the market average51.85% below the market average51.85% below the market average51.85% below the market average51.85% below the market average
73.91% below the sector average73.91% below the sector average73.91% below the sector average73.91% below the sector average73.91% below the sector average
Value
51.85% below the market average51.85% below the market average51.85% below the market average51.85% below the market average51.85% below the market average
73.91% below the sector average73.91% below the sector average73.91% below the sector average73.91% below the sector average73.91% below the sector average
Income Not Available
Growth
23.68% above the market average23.68% above the market average23.68% above the market average23.68% above the market average23.68% above the market average
25.00% above the sector average25.00% above the sector average25.00% above the sector average25.00% above the sector average25.00% above the sector average

N4 Pharma Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

N4 Pharma Key Personnel

CEO Nigel Theobald

Top of Page